Thomas Barnes from Intellia Therapeutics gave a talk to Corn Lab

The management and research teams from Intellia Therapeutics came to visit UC Berkeley today. Thomas Barnes, Ph.D., the Senior Vice President of Innovative Sciences & eXtellia, and his teams shared their scientific expertise in CRISPR/Cas9 technology and clinical development experience to the members in Corn lab.

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

June 23, 2025

SWISSPR 2025

SWISSPR 2025, hosted by the Corn, Platt, Schwank, and Jinek labs, was a fantastic retreat that brought together cutting-edge CRISPR research at Seminarhotel...

May 12, 2025

Welcome to Dora!

Dora obtained her Master’s degree in Chemistry from ETH Zurich in 2019, where she conducted research on the Synthesis of trypanothione reductase inhibitors...

April 22, 2025

Welcome back to Dominic!

Dominic Mailänder received his Master’s degree in Molecular Health Sciences from ETH Zurich in 2024. Dominic returned to the Corn Lab as a Research ...

News Archive

Tweets